Dr. Ahmad Masri and Dr. C. Michael Gibson discuss findings presented at the HFSA2026 examining the association between an early eGFR dip following acoramidis initiation and the risk of all-cause mortality and recurrent cardiovascular-related hospitalizations.

The post hoc analysis of ATTRibute-CM found that acoramidis was associated with a consistent benefit on these outcomes through month 30, regardless of the magnitude of the Day 28 eGFR dip. No clinically concerning changes in laboratory parameters or blood pressure were observed.

Sponsored by an independent educational grant from BridgeBio Inc.